Cargando…

Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council

BACKGROUND: The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome measure designed to assess psoriasis signs and symptoms. OBJECTIVES: The aim was to assess the usefulness of the PSI in enhancing patient care in the clinical setting. METHODS: Eight dermatology clinics in six countries...

Descripción completa

Detalles Bibliográficos
Autores principales: Strober, Bruce, van de Kerkhof, Peter C. M., Callis Duffin, Kristina, Poulin, Yves, Warren, Richard B., de la Cruz, Claudia, van der Walt, Joelle M., Stolshek, Bradley S., Martin, Mona L., de Carvalho, Andre V. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764927/
https://www.ncbi.nlm.nih.gov/pubmed/31228013
http://dx.doi.org/10.1007/s40257-019-00458-2
Descripción
Sumario:BACKGROUND: The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome measure designed to assess psoriasis signs and symptoms. OBJECTIVES: The aim was to assess the usefulness of the PSI in enhancing patient care in the clinical setting. METHODS: Eight dermatology clinics in six countries enrolled adults representing the full spectrum of psoriasis severity who regularly received care at the clinic. Patients were administered the eight-item PSI (score range 0–32; higher scores indicate greater severity) while waiting for the physician; the physician conducted a static physician global assessment (sPGA) and estimated psoriasis-affected body surface area (BSA) at the same visit. Physicians completed a brief questionnaire after each patient visit, and were interviewed about the PSI after all patients were seen. RESULTS: The clinics enrolled 278 patients; mean [standard deviation (SD)] psoriasis-affected BSA was 7.6% (11.4). Based on BSA, 47.8% had mild psoriasis, 29.1% had moderate psoriasis, and 23.0% had severe psoriasis. Based on sPGA, 18.7% were clear/almost clear, 67.3% were mild/moderate, and 14.0% were severe/very severe. The mean (SD) PSI total score was 12.2 (8.3). Physicians spent a mean (SD) 4.9 (4.8) min discussing PSI findings with their patients (range 0–20 min). Key benefits of PSI discussions included the following: new information regarding symptom location and severity for physicians; prompting of quality-of-life discussions; better understanding of patient treatment priorities; change in treatment regimens to target specific symptoms or areas; and improvement of patient–physician relationship. CONCLUSIONS: The PSI was useful for treated and untreated patients to enhance patient–physician communication, and influenced treatment decisions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40257-019-00458-2) contains supplementary material, which is available to authorized users.